Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

Adjuvant Cemiplimab Cleared in EU for CSCC With High Recurrence Risk After Surgery and Radiation

November 19th 2025

Cemiplimab wins EU approval after C-POST shows DFS gains for high-risk CSCC, marking the first effective adjuvant immunotherapy option.

FDA Approves Selumetinib for Adult NF1-Associated Plexiform Neurofibromas

November 19th 2025

The FDA approved selumetinib for the treatment of adults with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.

FDA Approval of Lurbinectedin/Atezolizumab As First-Line Maintenance Expands Limited Post-Induction Arsenal for ES-SCLC

November 18th 2025

Joshua K. Sabari, MD, discusses the FDA approval of lurbinectedin plus atezolizumab as first-line maintenance therapy in extensive-stage SCLC.

Targeted Strategies Push the Envelope for BRAF V600E–, MET Exon 14–, and KRAS G12C–Mutated Metastatic NSCLC

November 17th 2025

Gregory J. Riely, MD, PhD, discusses targeted approaches for BRAF V600E, MET exon 14, and KRAS G12C mutations in metastatic NSCLC.

Additional Biomarkers Are Needed to Inform ADC Selection in NSCLC

November 15th 2025

Benjamin P. Levy, MD, discusses advances with ADCs in lung cancer during the 20th Annual New York Lung Cancers Symposium.

Immunotherapy Advances in SCLC Highlight Promise, Limitations, and Biomarker Needs

November 15th 2025

Christine Hann, MD, PhD, discusses how recently presented SCLC data inform treatment decision-making across the LS-SCLC and ES-SCLC settings.

Dr Desai on the Treatment Landscape of Polycythemia Vera

November 14th 2025

Ruchi J. Desai, MD, discusses the treatment landscape of polycythemia vera and unmet needs in the space.

B7-H3–Targeted ADC HN-20093 Shows Strong Efficacy, Is Still Safe at Higher Dose in R/R Sarcomas

November 14th 2025

Lu Xie, MD, discusses phase 2 efficacy and safety data with the B7-H3–targeted ADC HS-20093 in relapsed/refractory sarcomas.

Adjuvant Satri-Cel Displays Preliminary Activity in Pancreatic Ductal Adenocarcinoma

November 14th 2025

Satri-cel displayed preliminary efficacy when used as adjuvant treatment in patients with pancreatic ductal adenocarcinoma.

Dr Jakubowiak on How the PERSEUS Study Informed the ATLAS Trial in Multiple Myeloma

November 13th 2025

Andrzej Jakubowiak, MD, PhD, discusses how the data from the PERSEUS Study informed the ATLAS trial in multiple myeloma.

Dr Randall on the Need for Precision Survivorship Care in Pediatric and AYA Sarcoma

November 13th 2025

R. Lor Randall, MD, discusses the need to move beyond modest survival improvements in pediatric bone sarcoma toward equitable, precision survivorship care.

Dr Yuan on the Evolving Landscape of ADCs in HER2+ Breast Cancer

November 13th 2025

Yuan Yuan, MD, PhD, discussed the evolving landscape of therapeutic targets and payloads for ADCs in HER2-positive breast cancer.

FDA Grants 510(k) Clearance to EXENT System for Multiple Myeloma Diagnosis

November 13th 2025

The FDA granted 510(k) clearance to the EXENT System to aid in the diagnosis of multiple myeloma and related disorders.

FDA Accepts NDA For 177Lu-edotreotide for GEP-NETs

November 13th 2025

The NDA seeking approval of 177Lu-edotreotide for the treatment of patients with GEP-NETs has been accepted by the FDA.

Efforts to Leverage NaPi2b Are Renewed With Novel ADC in Ovarian Cancer

November 13th 2025

Initial activity and safety with the investigational ADC TUB-040 in ovarian cancer have renewed interest in NaPi2b as a target for ADC development.

Dr Visco on Ongoing Research to Optimize Upfront MCL Therapy

November 13th 2025

Carlo Visco, MD, discussed notable ongoing MCL research and the emerging challenge of optimally sequencing therapies for the management of this disease.

Dr Tagawa on the Safety Profile of Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI and ADT in PSMA+ mHSPC

November 12th 2025

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the safety profile of lutetium Lu 177 vipivotide tetraxetan plus ARPI and ADT in mHSPC.

Dr Orloff on OS Outcomes With Darovasertib Plus Crizotinib in Metastatic Uveal Melanoma

November 12th 2025

Marlana Orloff, MD, discusses efficacy findings with darovasertib plus crizotinib in metastatic uveal melanoma that were seen in the OptimUM-01 trial.

Dr Liu on the Efficacy of Zidesamtinib in ROS1 Fusion+ NSCLC

November 12th 2025

Stephen Liu, MD, discussed efficacy data with zidesamtinib in ROS1 fusion–positive non-small cell lung cancer that were reported in the ARROS-1 trial.

Dr Camidge on the Efficacy and Safety of Neladalkib in ALK+ Solid Tumors

November 12th 2025

D. Ross Camidge, MD, PhD, discusses safety and efficacy data seen with neladalkib in TKI-naive and -pretreated patients with ALK-positive solid tumors.